X0609 4 2026-09-11 true 0002081043 AtaiBeckley Inc. ATAI 0001845872 Angermayer Christian true 66 & 67, BEATRICE, AMERY STREET SLIEMA O1 SLM1707 MALTA true true 0001845711 Apeiron Investment Group Ltd. true 66 & 67 AMERY STREET SILEMA O1 SLM1707 MALTA true false Common Stock 2026-09-11 4 D 0 559232 D 0 D Common Stock 2026-09-11 4 D 0 53398214 D 0 I By ApeironInvestmentGroup Ltd. Common Stock 2026-09-11 4 D 0 1799302 D 0 I By ApeironPresightCapital FundII, L.P. Stock Option 5.68 2026-09-11 4 D 0 624000 D 2030-08-20 Common Stock 624000 0 D Stock Option 3.84 2026-09-11 4 D 0 64000 D 2032-05-25 Common Stock 64000 0 D Stock Option 1.88 2026-09-11 4 D 0 17930 D 2033-05-23 Common Stock 17930 0 D Stock Option 1.64 2026-09-11 4 D 0 1247932 D 2034-01-05 Common Stock 1247932 0 D Stock Option 2.49 2026-09-11 4 D 0 131698 D 2035-06-02 Common Stock 131698 0 D Stock Option 2.25 2026-09-11 4 D 0 103000 D 2035-06-26 Common Stock 103000 0 D Stock Option 4.5 2026-09-11 4 D 0 121968 D 2036-06-04 Common Stock 121968 0 D Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4. At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Apeiron Investment Group Ltd. By: /s/ Sanad Abushala, Director 2026-09-11 /s/ Ryan Barrett, Attorney-in-fact 2026-09-11